| Routes of|
CoviVac (Russian : КовиВак) is an inactivated virus-based COVID-19 vaccine developed by the Chumakov Centre , which is an institute of the Russian Academy of Sciences. It was approved for use in Russia in February 2021, being the third COVID-19 vaccine to get approval in Russia. It obtained a permission for phase III clinical trial on 2 June 2021.
The CoviVac shot is given in two doses, 14 days apart. It is transported and stored at normal refrigerated temperatures, of 2 to 8 degrees Celsius (35.6 to 46.4 Fahrenheit).
Efficacy has not yet been established in a phase III clinical trial.
One dose of 0.5 ml is composed only of 3 μg or more of SARS-CoV-2 strain AYDAR-1 antigen inactivated by beta-propiolactone and the following excipients:
As an inactivated vaccine, CoviVac uses a more traditional technology that is similar to the inactivated polio vaccine. Initially, a sample of SARS-CoV-2 strain AYDAR-1 was isolated by the Chumakov Center at the Russian Academy of Sciences and used to grow large quantities of the virus using vero cells. From then on, the viruses are soaked in beta-propiolactone, which deactivates them by binding to their genes, while leaving other viral particles intact. The resulting inactivated viruses are then mixed with an aluminium-based adjuvant.
On September 21, 2020, phase I/II trials started and was expected to last through October 15, 2020.
In early 2021, phase III trials started and is expected to end on 30 December 2022.
On 20 February 2021, President Vladimir Putin announced that the vaccine was approved.
Sinovac Biotech Ltd. is a Chinese biopharmaceutical company that focuses on the research, development, manufacture, and commercialization of vaccines that protect against human infectious diseases. The company is based in Haidian District, Beijing in China. The company was listed on the NASDAQ but the exchange halted Sinovac's trading in February 2019 due to a proxy fight. The company has faced bribery probes in China.
An inactivated vaccine is a vaccine consisting of virus particles, bacteria, or other pathogens that have been grown in culture and then killed to destroy disease-producing capacity. In contrast, live vaccines use pathogens that are still alive. Pathogens for inactivated vaccines are grown under controlled conditions and are killed as a means to reduce infectivity and thus prevent infection from the vaccine.
A COVID‑19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), the virus that causes coronavirus disease 2019 (COVID‑19). Prior to the COVID‑19 pandemic, an established body of knowledge existed about the structure and function of coronaviruses causing diseases like severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). This knowledge accelerated the development of various vaccine platforms during early 2020. The initial focus of SARS-CoV-2 vaccines was on preventing symptomatic, often severe illness. On 10 January 2020, the SARS-CoV-2 genetic sequence data was shared through GISAID, and by 19 March, the global pharmaceutical industry announced a major commitment to address COVID‑19. The COVID‑19 vaccines are widely credited for their role in reducing the severity and death caused by COVID‑19.
Sputnik V or Gam-COVID-Vac is an adenovirus viral vector vaccine for COVID-19 developed by the Gamaleya Research Institute of Epidemiology and Microbiology in Russia. It is the world's first registered combination vector vaccine for the prevention of COVID-19, having been registered on 11 August 2020 by the Russian Ministry of Health.
CoronaVac, also known as the Sinovac COVID-19 vaccine, is an inactivated virus COVID-19 vaccine developed by the Chinese company Sinovac Biotech. It was Phase III clinical trialled in Brazil, Chile, Indonesia, the Philippines, and Turkey and relies on traditional technology similar to other inactivated-virus COVID-19 vaccines, such as the Sinopharm BIBP vaccine, another Chinese vaccine, and Covaxin, an Indian vaccine. CoronaVac does not need to be frozen and both the final product and the raw material for formulating CoronaVac can be transported refrigerated at 2–8 °C (36–46 °F), temperatures at which flu vaccines are kept.
Covaxin is an inactivated virus-based COVID-19 vaccine developed by Bharat Biotech in collaboration with the Indian Council of Medical Research - National Institute of Virology.
Valneva COVID-19 vaccine, also known as the VLA2001 and VLA2101 , is a COVID-19 vaccine candidate developed by French biotechnology company Valneva SE in collaboration with American company Dynavax Technologies.
ZF2001, trade-named Zifivax or ZF-UZ-VAC-2001, is an adjuvanted protein subunit COVID-19 vaccine developed by Anhui Zhifei Longcom in collaboration with the Institute of Microbiology at the Chinese Academy of Sciences. The vaccine candidate is in Phase III trials with 29,000 participants in China, Ecuador, Malaysia, Pakistan, and Uzbekistan.
EpiVacCorona is a peptide-based vaccine against COVID-19 developed by the VECTOR center of Virology. It consists of three chemically synthesized peptides that are conjugated to a large carrier protein. This protein is a fusion product of a viral nucleocapsid protein and a bacterial MBP protein. The third phase of a clinical trial, which should show whether the vaccine is able to protect people from COVID-19 or not, was launched in November 2020 with more than three thousand participants.
The COVID-19 vaccination campaign in Russia is an ongoing mass immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country. Mass vaccinations began in December 2020, starting with primarily doctors, medical workers and teachers, and in January 2021, this was extended to the entire population.
SCB-2019 is a protein subunit COVID-19 vaccine developed by Clover Biopharmaceuticals using an adjuvant from Dynavax technologies. Positive results of Phase I trials for the vaccine were published in The Lancet and the vaccine completed enrollment of 29,000 participants in Phase II/III trials in July 2021. In September 2021, SCB-2019 announced Phase III results showing 67% efficacy against all cases of COVID-19 and 79% efficacy against all cases of the Delta variant. Additionally, the vaccine was 84% effective against moderate cases and 100% effective against hospitalization.
QazCovid-in, commercially known as QazVac, is a COVID-19 vaccine developed by the Research Institute for Biological Safety Problems in Kazakhstan. QazCoVac-P is a second COVID-19 vaccine developed by the Kazakh Biosafety Research Institute and in clinical trials.
The Sinopharm WIBP COVID-19 vaccine, also known as WIBP-CorV, is one of two inactivated virus COVID-19 vaccines developed by Sinopharm. Peer-reviewed results show that the vaccine is 72.8% effective against symptomatic cases and 100% against severe cases. The other inactivated virus COVID-19 vaccine developed by Sinopharm is the BIBP vaccine (BBIBP-CorV) which is comparably more successful. 1 billion doses are expected to be produced per year.
UB-612 is a COVID-19 vaccine candidate developed by United Biomedical, Inc. Asia, Vaxxinity, and DASA. It is a peptide vaccine.
West China Hospital COVID-19 vaccine is a COVID-19 vaccine candidate developed by Jiangsu Province Centers for Disease Control and Prevention, West China Hospital and Sichuan University.
TURKOVAC is a COVID-19 vaccine candidate developed by Health Institutes of Turkey and Erciyes University.
NDV-HXP-S is a COVID-19 vaccine candidate developed by a team led by Jason McLellan at the University of Texas at Austin, together with groups from the Icahn School of Medicine at Mount Sinai and the National Institute of Allergy and Infectious Diseases Vaccine Research Center, based on an improved spike protein central to its resilience and efficacy.
CoviVac may refer to:
COVI-VAC is a COVID-19 vaccine developed by Codagenix, Inc. As of December 2020, COVI-VAC was undergoing a Phase I clinical trial, involving 48 participants. The trial was scheduled to complete in June 2021, with results reported by May 2022.
COVID-19 vaccine clinical research uses clinical research to establish the characteristics of COVID-19 vaccines. These characteristics include efficacy, effectiveness and safety. 26 vaccines are authorized for use by national governments, including seven approved for emergency or full use by at least one WHO-recognised stringent regulatory authority; while five are in Phase IV. 204 vaccines are undergoing clinical trials that have yet to be authorized. Nine clinical trials consider heterologous vaccination courses.
|Scholia has a profile for CoviVac (Q105597762).|